XML 26 R16.htm IDEA: XBRL DOCUMENT v3.7.0.1
Recently Added Product
6 Months Ended
Jun. 30, 2017
Business Combinations [Abstract]  
RECENTLY ADDED PRODUCT
TOTECT DISTRIBUTION
Totect
On July 31, 2017, the Company initiated distribution and sale of Totect in the United States. This followed the FDA approval of the product manufacturer and updated labeling for the product.
Totect is an FDA approved emergency oncology intervention which is indicated to treat the toxic effects of anthracycline chemotherapy in case of extravasation. Extravasation occurs when an injected medicine escapes from the blood vessels and circulates into surrounding tissues in the body causing severe damage and serious complications. Totect can limit such damage without the need for additional surgeries and procedures, enabling patients to continue their essential anti-cancer treatment.
In January 2017, the Company announced an agreement to acquire the exclusive rights to the oncology support drug Totect in the United States. This was the second product Clinigen has licensed to us under our strategic alliance. Under the terms of the agreement, Cumberland is managing all marketing, promotion, and distribution of the product in the United States.